Cancer and the microbiota
Open accessThe DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
A host’s microbiota may increase, diminish, or have no effect at all on cancer susceptibility. Assigning causal roles in cancer to specific microbes and microbiotas, unraveling host-microbiota interactions with environmental factors in carcinogenesis, and exploiting such knowledge for cancer diagnosis and treatment are areas of intensive interest. This Review considers how microbes and the microbiota may amplify or mitigate carcinogenesis, responsiveness to cancer therapeutics, and cancer-associated complications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Loss of microbial diversity (dysbiosis) is associated with chronic health conditions (26–28) and cancer (8–10), and is also associated with poor outcomes to certain forms of cancer therapy including allogeneic stem cell transplant (29).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [8]
In the citing paper
“It has recently emerged that factors beyond tumor genomics influence cancer development and therapeutic responses (4–7), including host factors such as the gastrointestinal (gut) microbiome (8–10).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [8]
In the citing paper
“their gene count that exceeds the human genome’s gene count by ~100-fold and enables diverse metabolic programming”
From The microbiome and human cancer (2021) · cites this paper as [31]
In the citing paper
“the number of microbes that inhabit the human body (roughly equal to the number of human cells)”
From The microbiome and human cancer (2021) · cites this paper as [31]
In the citing paper
“their effects on host immune system development and activity, including antitumor immunosurveillance (27–31).”
From The microbiome and human cancer (2021) · cites this paper as [31]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
A core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
Self-citationMetabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Interactions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Inflammatory Mechanisms in Obesity
Gregor, M. F., & Hotamisligil, G. S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101322 · Cited by 3,754
Research works printed but not linked: 1
- 10.1111/j.1572-0241.2000.01860.x · doi:10.1111/j.1572-0241.2000.01860.x · Paper page
Cited by
Items 601–700 of 1,001
Qin, W., Wang, S., Min, Y., Liu, X., Fang, J., Lang, J., & Chen, M. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03599-1 · Cited by 29
Sex differences in bladder cancer: understanding biological and clinical implications
Chaudhary, P., Singha, B., Abdel-Hafiz, H. A., Velegraki, M., Sundi, D., Satturwar, S. P., Parwani, A. V., Grivennikov, S. I., You, S., Goodridge, H. S., et al. (2025) · Biology of Sex Differences · doi:10.1186/s13293-025-00715-6 · Cited by 30
“Research suggests that over one-fifth of malignant tumors may involve microbiota influences [212].”
Composition of fecal microbiota in low-set rectal cancer patients treated with FOLFOX
Li, J., Li, J., Lyu, N., Ma, Y., Liu, F., Feng, Y., Li, Y., Hou, Z., Song, X., Zhao, H.-C., et al. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320904293 · Cited by 26
Reticker-Flynn, N. E., & Engleman, E. G. (2020) · eLife · doi:10.7554/elife.53839 · Cited by 26
Wang, Y., Yang, S., Wan, L., Ling, W., Chen, H. H., & Wang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5534 · Cited by 24
Diversification and deleterious role of microbiome in gastric cancer
Chattopadhyay, I., Gundamaraju, R., & Rajeev, A. (2023) · Cancer Reports · doi:10.1002/cnr2.1878 · Cited by 23
The microbiome and gynecologic cancer: cellular mechanisms and clinical applications
Chalif, J., Wang, H., Spakowicz, D. J., Quick, A. M., Arthur, E. K., O’Malley, D. M., & Chambers, L. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2023-004894 · Cited by 28
Human Intestinal Microbiota and Colorectal Cancer: Moving Beyond Associative Studies
Jobin, C. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.10.030 · Cited by 24
Liu, A.-Q., Vogtmann, E., Shao, D., Abnet, C. C., Dou, H.-Y., Yu, Q., Su, Z., Wei, W., & Chen, W. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-1210 · Cited by 21
“When the microbial balance is disturbed, the microbiota could alter host cell proliferation and death, manipulate the immune system, and influence host metabolism, giving rise to carcinoma (13).”
BackgroundThe role of non-H. pylori bacteria in the development of gastric cancer.
Li, Q., & Yu, H. (2020) · PubMed · Cited by 26
Insights in Waste Management Bioprocesses Using Genomic Tools
Purohit, H. J., Kapley, A., Khardenavis, A. A., Qureshi, A., & Dafale, N. A. (2016) · Advances in applied microbiology · doi:10.1016/bs.aambs.2016.09.002 · Cited by 22
Interaction Between the Polysaccharides and Proteins in Semisolid Food Systems
Zhang, M., Sun, C., & Li, Q. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-100596-5.21474-1 · Cited by 21
Li, J., Zhou, W., Wang, H., Huang, M., & Deng, H. (2024) · MedComm · doi:10.1002/mco2.70019 · Cited by 27
Chen, Y., Huang, Y., Li, W., Zhu, T., Cheng, M., Wu, C., Zhang, L., Peng, H., & Wang, K. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06369-7 · Cited by 26
“Moreover, increasing data highlight that tumor microbiome is a potential modulator of immune responses and therapeutic efficacy across multiple cancer types [16, 17].”
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma
Masouleh, S. S., Nasiri, K., Ravari, A. O., Rad, M. S., Kiani, K., Sultani, A. S., Nejati, S. T., & Nabi‐Afjadi, M. (2025) · Biomarker Research · doi:10.1186/s40364-025-00783-1 · Cited by 24
“The high antigen heterogeneity within individual tumors also complicates the identification of reliable biomarkers for therapy selection, limiting the development of effective targeted therapies [136–138].”
Gut Feelings: How Microbes, Diet, and Host Immunity Shape Disease
Theis, B. F., Park, J. S., Kim, J. S., Zeydabadinejad, S., Vijay–Kumar, M., Yeoh, B. S., & Saha, P. (2025) · Biomedicines · doi:10.3390/biomedicines13061357 · Cited by 25
Huang, T., Debelius, J. W., Ploner, A., Xiao, X., Zhang, T., Hu, K., Zhang, Z., Wang, R., & Ye, W. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.08.054 · Cited by 22
Fan, X., Xiao, X., Mao, X., Chen, D., Yu, B., Wang, J., & Yan, H. (2020) · IUBMB Life · doi:10.1002/iub.2445 · Cited by 20
Enteropathogenic Infections: Organoids Go Bacterial
Hentschel, V., Arnold, F., Seufferlein, T. T. W., Azoitei, N., Kleger, A., & Müller, M. (2021) · Stem Cells International · doi:10.1155/2021/8847804 · Cited by 22
“Malignant transformation can be achieved by promotion of an in fl ammatory environment, production of molecules a ff ecting DNA stability, and alteration of proliferative responses [92].”
BackgroundGut microbes in gastrointestinal cancers
Wang, F., Song, M., Lu, X., Zhu, X., & Deng, J. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.037 · Cited by 23
The Role of Gut Microbiota in Gastrointestinal Tract Cancers
Grochowska, M., Perlejewski, K., Laskus, T., & Radkowski, M. (2022) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-021-00641-6 · Cited by 23
“Research on the role of specific bacteria and interactions between the host and microbiota in oncogenesis is progressing rapidly and is likely to provide new opportunities for cancer prevention and therapy (Garrett 2015).”
BackgroundInfluentialCandida albicans induces upregulation of programmed death ligand 1 in oral squamous cell carcinoma
Wang, X., Zhao, W., Zhang, W., Wu, S., & Yan, Z. (2022) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.13298 · Cited by 20
Cheng, Z., Wang, Y., & Li, B. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c02654 · Cited by 20
Loganathan, T., & Doss, C. G. P. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121118 · Cited by 22
Trifanescu, O. G., Trifanescu, R. A., Mitrica, R. I., Bran, D. M., Serbanescu, L. G., Valcauan, L., Marinescu, Ș. A., Gales, L. N., Tănase, B. C., & Anghel, R. M. (2023) · Diagnostics · doi:10.3390/diagnostics13050877 · Cited by 27
“, thus exhibiting low bacterial diversity and protecting against carcinogenesis through various mechanisms [25].”
BackgroundDiet-gut microbial interactions influence cancer immunotherapy
Wang, X., & Geng, S.-T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1138362 · Cited by 23
“Increasing evidence suggests that gut microbiota can influence the susceptibility and etiology of cancer (19).”
BackgroundNarayanan, A., Söder, B., Meurman, J. H., Lundmark, A., Hu, Y. O. O., Neogi, U., & Yucel‐Lindberg, T. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1172340 · Cited by 24
“Some have proposed that the association between periodontitis and the risk of different types of cancer is due to the chronic inflammation caused by periodontitis, which drives cancer development by infiltration of leukocytes in the tumor microenvironment (Hanke et al., 1990; Garrett, 2015).”
BackgroundInfluentialGut and urinary microbiota: the causes and potential treatment measures of renal cell carcinoma
Yang, J.-W., Wan, S., Li, K., Chen, S., & Yang, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188520 · Cited by 26
“Previous studies suggest that microorganisms can induce tumorigenesis through several primary mechanisms (1): pathogenic microorganisms directly interact with host tissue cells, causing tissue cell death and repair, and driving normal tissue cells to transform into tumor cells by affecting genome stability, anti-cell…”
BackgroundGut microbiota in cancer initiation, development and therapy
Zhang, R., Zhang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2831-x · Cited by 19
“…of cell proliferation and apoptosis signaling pathways, (ii) interacting with host genetic and epigenetic alterations, (iii) inducing chronic inflammation, (iv) altering immune system responses, and (v) influencing the co-metabolism of host and dietary substances (Garrett, 2015; Wong and Yu, 2023).”
Microbes Saving Lives and Reducing Suffering
Timmis, K. N., Karahan, Z. C., Ramos, J. L., Koren, O., Pérez‐Cobas, A. E., Steward, K. F., de Lorenzo, V., Caselli, E., Douglas, M., Schwab, C., et al. (2025) · Microbial Biotechnology · doi:10.1111/1751-7915.70068 · Cited by 24
Bacterial dysbiosis incites Th17 cell revolt in irradiated gut
Shao, L., Li, M., Zhang, B., & Chang, P. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110674 · Cited by 21
Läsche, M., Gallwas, J. K. S., & Gründker, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095050 · Cited by 26
“Only in the case of a continued infection, which may last for several years, and which is perhaps also supported by an accompanying “pathological” microbiota [84], the immune system no longer manages to completely eliminate the infection, which increases the risk of transformation of the cervical epithelium [85,86].”
BackgroundGut microbiota: a potential target for improved cancer therapy
Zhao, M., Jiang, G., Zhou, H., Li, J., Xiang, W., Li, S., Wang, H., & Zhou, J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04546-5 · Cited by 20
“Dysbiosis of the gut microbiota can lead to the development of various cancers (Garrett 2015).”
BackgroundSasaki, T., Matsumoto, Y., Murakami, K., Endo, S., Toyozumi, T., Otsuka, R., Kinoshita, K., Hu, J. H., Iida, S., Morishita, H., et al. (2023) · Esophagus · doi:10.1007/s10388-023-01004-0 · Cited by 19
Zhou, C., Huang, Y., Da, M., Jin, W., & Zhou, F. (2023) · Discover Oncology · doi:10.1007/s12672-023-00704-4 · Cited by 22
The role of extratumoral and intratumoral microorganisms in cancer immunotherapy
Du, Y., Liu, L., Ma, W., Yan, W., Mao, W., Du, Y., Cui, K., Pu, Y., Li, Z., Sansonetti, P. J., et al. (2023) · The Innovation Life · doi:10.59717/j.xinn-life.2023.100016 · Cited by 21
Exploring the human microbiome – A step forward for precision medicine in breast cancer
Jotshi, A., Sukla, K. K., Haque, M. M., Bose, C., Varma, B., Koppiker, C. B., Joshi, S., & Mishra, R. (2023) · Cancer Reports · doi:10.1002/cnr2.1877 · Cited by 25
Microbiota: A key factor affecting and regulating the efficacy of immunotherapy
Jiang, Y., Jia, D., Sun, Y., Ding, N., & Wang, L. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1508 · Cited by 22
Xin, H., Zou, J., Sun, R., Hu, Z., Chen, Z., Luo, C., Zhou, Z., Wang, P., Li, J., Yu, S., et al. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02090-2 · Cited by 19
“A previous study showed that tumor microbiota could promote tumor progression via influencing the genomic and immune micro-environments [6].”
InfluentialYang, K., Wang, S. L., Ding, Z., Zhang, K., Zhu, W., Wang, H., Pan, M., Li, X., Wang, H., & Yu, Z. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1397989 · Cited by 22
“…through which microbiota contribute to tumor initiation and progression: (1) modulation of cell proliferation and apoptosis pathways, (2) modulation of the immune system and immune responses, and (3) modulation of host secretion factors, as well as metabolism of food and drugs (Garrett, 2015).”
Ma, X., Liu, P., Tian, Y., Zhu, G., Yang, P. H., Wang, G., & Yang, L. (2018) · Nanoscale · doi:10.1039/c7nr07714a · Cited by 19
Innate lymphoid cells: A potential link between microbiota and immune responses against cancer
Panda, S. K., & Colonna, M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.03.003 · Cited by 23
CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy
Sacchetti, B., Botticelli, A., Pierelli, L., Nuti, M., & Alimandi, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081903 · Cited by 20
“…with specific immune components to induce conversion from non-inflammatory to pro-inflammatory environments through synthesis of regulatory cytokines and, in some cases, influencing the PD-1-PD-L1 signaling axis, holding in check the activation/inhibition balance of the immune responses [74– 76 ,”
Shahid, U. (2025) · The Journal of Precision Medicine Health and Disease · doi:10.1016/j.premed.2025.100018 · Cited by 34
Engineered bacteria for cancer therapy: Advancements, challenges, and future directions
Wang, M.-G., Liu, M., Wang, D., Yang, D., Zeng, Y., Lan, Y., & Wang, Q. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003807 · Cited by 19
“…such as maintaining optimal colonic conditions (e.g., pH and bile acid profiles), [88] modulating the gut microbiota by producing short-chain fatty acids, [89,90] reducing the levels of harmful bacteria that produce the mutagenic enzymes, [91] and performing immunomodulatory activities [Figure 1].”
Malagón, M., Ramió‐Pujol, S., Serrano, M., Serra‐Pagès, M., Amoedo, J., Oliver, L., Bahí, A., Mas-De-Xaxars, T., Torrealba, L., Gilabert, P., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15251 · Cited by 30
Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers
Elbehi, M. A., I, A. R., Ekine-Afolabi, B. A., & Cash, E. D. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104977 · Cited by 23
Schmiester, M., Maier, R., Riedel, R., Durek, P., Frentsch, M., Kolling, S., Mashreghi, M., Jenq, R. R., Zhang, L., Peterson, C. B., et al. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2081475 · Cited by 21
“For malignant diseases, mounting evidence suggests a complex involvement of the commensal gut microbiota in the formation and progression of neoplasms and in the effectiveness of antineoplastic therapy.(3,4) The microbial composition has been associated with response to immunotherapy in malignant melanoma and with the…”
BackgroundChai, L., Jabbie, I. S., Chen, A., Jiang, L., Li, M., & Rao, H. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-22143-4 · Cited by 18
Circulating Bacterial DNA as Plasma Biomarkers for Lung Cancer Early Detection
Zhou, H., Liao, J., Leng, Q., Chinthalapally, M., Dhilipkannah, P., & Jiang, F. (2023) · Microorganisms · doi:10.3390/microorganisms11030582 · Cited by 20
“It has been proposed that the microbiome plays a crucial role in tumor development through various mechanisms, including disruption of local immune barriers, toxin production, genome instability, and release of tumor-promoting metabolites [2].”
BackgroundImmuno-oncology-microbiome axis of gastrointestinal malignancy
Lin, Q., Guan, S.-W., & Yu, H. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i5.757 · Cited by 28
Garg, S., Sharma, N., Bharmjeet, & Das, A. (2023) · Cancer Reports · doi:10.1002/cnr2.1892 · Cited by 27
“15 However, scientists have given evidence to suggest a strong connection between microbial infections and cancer.”
BackgroundLuan, B., Ge, F., Lu, X., Li, Z., Zhang, H., Wu, J., Yang, Q., Chen, L., Zhang, W., & Chen, W. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03373-5 · Cited by 20
“…source for endogenous metabolite production, signaling molecules that activate host G-protein-coupled receptors (GPCRs), contributing to the regulation of histone deacetylases (HDACs), the nuclear factor 2-related erythroid 2 (Nrf2) signaling pathway, and influencing host gene expression [35–37].”
Obesity and Cancer: Concepts and Challenges
Argolo, D. F. S. D. T. E., Iyengar, N. M., & Hudis, C. A. (2015) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-015-0483-z · Cited by 19
Wang, Q., Li, L., & Xu, R. (2018) · Scientific Reports · doi:10.1038/s41598-018-24315-0 · Cited by 22
Balhouse, B. N., Patterson, L., Schmelz, E. M., Slade, D. J., & Verbridge, S. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180372 · Cited by 22
Pérez-Ruiz, E., Jiménez-Castro, J., Berciano‐Guerrero, M., Valdivia, J., Estalella-Mendoza, S., Toscano, F., Artacho, M. R. D. L. B., Garrido-Siles, M., Bautista, M. J. M., Roldán, R. V., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02315-9 · Cited by 20
The Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies?
Brandi, G., Turroni, S., McAllister, F. M., & Frega, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189914 · Cited by 21
“Even though cancer is perceived as a genetic disease, 13% of human malignancies, and probably a higher percentage in other animal species, are more or less strictly dependent on microorganisms in their etiopathogenesis [22,23].”
BackgroundThe implementation of omics technologies in cancer microbiome research
Mullish, B. H., Osborne, L. S., Marchesi, J. R., & McDonald, J. A. K. (2018) · ecancermedicalscience · doi:10.3332/ecancer.2018.864 · Cited by 19
Intratumoral Fusobacterium nucleatum in Pancreatic Cancer: Current and Future Perspectives
D’Antonio, D. L., Zenoniani, A., Umme, S., Piattelli, A., & Curia, M. C. (2024) · Pathogens · doi:10.3390/pathogens14010002 · Cited by 24
“But when this balance does not work efficiently, a condition of dysbiosis is established, and the microbiota can induce proinflammatory or immunosuppressive responses that can stimulate tumorigenesis [50,51].”
Okuda, S., Hirose, Y., Takihara, H., Okuda, A., Ling, Y., Tajima, Y., Shimada, Y., Ichikawa, H., Takizawa, K., Sakata, J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-12658-8 · Cited by 21
Oral microbiota may predict the presence of esophageal squamous cell carcinoma
Jiang, Z., Wang, J., Qian, X., Zhang, Z., & Wang, S. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04393-4 · Cited by 17
“1 3 1 3 Increasing evidence has shown the crucial roles of bacterial infections in tumor development, including esophageal cancers (Garrett 2015).”
BackgroundSambruni, G., Macandog, A. D. G., Wirbel, J., Cagnina, D., Catozzi, C., Dallavilla, T., Borgo, F., Fazio, N., Romario, U. F., Petz, W. L., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01180-9 · Cited by 20
Han, W., Wang, N., Han, M., Liu, X., Sun, T., & Xu, J. (2023) · Cancer Medicine · doi:10.1002/cam4.6503 · Cited by 19
Piawah, S., Kyaw, T. S., Trepka, K. R., Stewart, A. L., Mora, R. V., Stanfield, D., Levine, K., Blarigan, E. L. V., Venook, A. P., Turnbaugh, P. J., et al. (2023) · Cancers · doi:10.3390/cancers15184546 · Cited by 17
Kalinen, S., Kallonen, T., Gunell, M., Ettala, O. O., Jambor, I., Knaapila, J., Syvänen, K. T., Taimen, P., POUTANEN, M. H., Aronen, H. J., et al. (2024) · European Urology Open Science · doi:10.1016/j.euros.2024.02.004 · Cited by 22
“Chronic inflammation, production of superoxide radicals, growth factors, and bacterial genotox-ins have all been proposed as mechanisms of action [7].”
BackgroundInfluentialZhao, H., Zhang, L., Du, D., Mai, L., Liu, Y., Morigen, M., & Fan, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113195 · Cited by 25
Peng, Y., Tang, Q., Wu, S., & Zhao, C. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10851-4 · Cited by 25
“Persistent infections caused by dysregulated microorganisms create a pro-inflammatory environment that promotes the occurrence of cancer [7–11].”
Importance of Probiotics in Cancer Prevention and Treatment
Sharma, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-816328-3.00004-0 · Cited by 18
Mikołajczyk, A., & Złotkowska, D. (2019) · Toxins · doi:10.3390/toxins11020091 · Cited by 19
Metaproteomic analysis of human gut microbiome in digestive and metabolic diseases
Pan, S., & Chen, R. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.12.002 · Cited by 22
Chang, Y., Liu, T., Liu, P., Meng, L., Li, S., Guo, Y., Yang, L., & Ma, X. (2020) · Chemical Communications · doi:10.1039/d0cc02546a · Cited by 17
What Is Known about Theragnostic Strategies in Colorectal Cancer
Parisi, A., Porzio, G., Pulcini, F., Cannita, K., Ficorella, C., Mattei, V., & Monache, S. D. (2021) · Biomedicines · doi:10.3390/biomedicines9020140 · Cited by 17
“For this purpose, numerous evidence has demonstrated that a direct relationship between modification in the gut microbiota composition and some pathologies exist [68,69].”
BackgroundGao, Y., Ma, L., & Su, J. (2022) · Microbiological Research · doi:10.1016/j.micres.2022.127113 · Cited by 17
Joukar, F., Mavaddati, S., Mansour‐Ghanaei, F., & Samadani, A. A. (2019) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-019-00237-6 · Cited by 19
Commensal microbes and p53 in cancer progression
Celardo, I., Melino, G., & Amelio, I. (2020) · Biology Direct · doi:10.1186/s13062-020-00281-4 · Cited by 17
“A deep understanding of the consequences of gut dysbiosis and the molecular basis of these represent a priority to direct research efforts in the area of cancer pathogenesis [30].”
The Spatial Features and Temporal Changes in the Gut Microbiota of a Healthy Chinese Population
Zhang, W., Han, N., Zhang, T., Qiang, Y., Peng, X., Li, X., & Kan, B. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01310-22 · Cited by 19
Hatayama, K., Kono, K., Okuma, K., Hasuko, K., Masuyama, H., & Benno, Y. (2023) · Biomedicines · doi:10.3390/biomedicines11020376 · Cited by 19
“These diseases include inflammatory bowel disease [7], allergies (such as Japanese cedar pollinosis [8,9]), autoimmune diseases (such as systemic lupus erythematosus and rheumatoid arthritis [10,11]), lifestyle-related diseases (for example, obesity and diabetes [12–14]), liver diseases (such as liver cirrhosis and no…”
BackgroundMattiola, I., & Diefenbach, A. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101724 · Cited by 19
Efficient Mining of Anticancer Peptides from Gut Metagenome
Ma, Y., Liu, X., Zhang, X., Yu, Y., Li, Y., Song, M., & Wang, J. (2023) · Advanced Science · doi:10.1002/advs.202300107 · Cited by 17
From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
Rodríguez‐Lara, A., Rueda‐Robles, A., Sáez‐Lara, M. J., Plaza‐Díaz, J., & Álvarez‐Mercado, A. I. (2023) · Pathogens · doi:10.3390/pathogens12070940 · Cited by 18
Pancreatic Cancer and Detection Methods
Ungkulpasvich, U., Hatakeyama, H., Hirotsu, T., & di Luccio, E. (2023) · Biomedicines · doi:10.3390/biomedicines11092557 · Cited by 19
“Moreover, several studies have demonstrated an unambiguous correlation between human microbiota and PC development [57,58], particularly regarding gastrointestinal and pancreatic microbes, as well as viral infections such as hepatitis and bile [59,60].”
BackgroundTumor-associated microbiome features of metastatic colorectal cancer and clinical implications
An, H. J., Partha, M. A., Lee, H., Lau, B. T., Pavlichin, D. S., Almeda, A. F., Hooker, A. C., Shin, G. W., & Ji, H. P. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1310054 · Cited by 17
“Microbial dysbiosis contributes to the pathophysiology of human diseases, including colorectal cancer (CRC), which has a close physical proximity with the diverse microbial populations in the colon (1, 2).”
BackgroundCheng, C., Wang, Z., Ding, C., Liu, P., Xu, X., Li, Y., Yan, Y., Yin, X., Chen, B., & Gu, B. (2024) · Phenomics · doi:10.1007/s43657-023-00135-9 · Cited by 17
“Currently, the field of interaction between human microbiota and diseases is rapidly emerging, and their association has been demonstrated closely (Garrett 2019; Chen et al. 2022).”
Lei, Y., Li, M., Zhang, H., Deng, Y. H., Dong, X., Chen, P., Li, Y., Zhang, S., Li, C., Wang, S., et al. (2024) · mSphere · doi:10.1128/msphere.00672-24 · Cited by 19
Gut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy
Cheng, P., Shen, P., Shan, Y., Yu, Y., Deng, R., Chen, W., Lu, Y., & Wei, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626045 · Cited by 17
“…membrane antigen and Fc g receptor Effectively recruits immune cells and acts as cytotoxic agents – McEnaney et al., 2014 popular research topic (Vesely and Schreiber, 2013; Bachireddy et al., 2015; Garrett, 2015; Segre, 2015; Topalian et al., 2015; Drewes et al., 2016; Tran et al., 2017).”
BackgroundThe impact of microbiome in urological diseases: a systematic review
Li, J. K. M., Chiu, P. K., & Ng, C. (2019) · International Urology and Nephrology · doi:10.1007/s11255-019-02225-y · Cited by 17
Gu, C., Sha, G., Zeng, B., Cao, H., Cao, Y., & Tang, D. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251327167 · Cited by 17
“42 The gut commensal microbiota resists pathogen colonization mainly through inter-microbial competition for nutrients and space.”
Gut microbiota — bidirectional modulator: role in inflammatory bowel disease and colorectal cancer
Cui, X., Li, C., Zhong, J., Liu, Y., Xiao, P., Liu, C., Zhao, M., & Yang, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1523584 · Cited by 17
“Some bacteria in the gut microbiome exert pro-cancer effects, while others have tumor suppressor properties (23).”
The intratumoral microbiota in breast cancer: from basic research to clinical translation
Xu, Y., & Wang, M. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2560695 · Cited by 22
Antimicrobial Prophylaxis and Modifications of the Gut Microbiota in Children with Cancer
Bossù, G., Sario, R. D., Argentiero, A., & Esposito, S. (2021) · Antibiotics · doi:10.3390/antibiotics10020152 · Cited by 15
“In children, it has been shown that a disrupted intestinal microbiota is linked to the development of a range of diseases (such as inflammatory bowel diseases [47], Kawasaki syndrome [48], asthma [49], autism [50–52]), and most importantly, dysbiosis itself plays an important role in cancerogenesis, alongside environm…”
BackgroundLaxative use and mortality in patients on haemodialysis: a prospective cohort study
Honda, Y., Itano, S., Kugimiya, A., Kubo, E., Yamada, Y., Kimachi, M., Shibagaki, Y., & Ikenoue, T. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02572-y · Cited by 17
Bacteria-Mediated Oncogenesis and the Underlying Molecular Intricacies: What We Know So Far
Prasad, S. K., Bhat, S., Shashank, D., Akshatha, C. R., Sindhu, R., Rachtanapun, P., Devegowda, D., Santhekadur, P. K., & Sommano, S. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836004 · Cited by 19
“This complex network in which a bacteria can possibly promote oncogenesis includes modified cell proliferation and death, alteration of the immune response, and change in the host metabolic processes (14).”
BackgroundLi, X., Sun, X., Zhang, A., Pang, J., Li, Y., Yan, M., Xu, Z., Yu, Y., Yang, Z., Chen, X., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.926920 · Cited by 16
Geng, Z.-H., Zhu, Y., Chen, W., Fu, P., Xu, J., Wang, T.-Y., Yao, L., Liu, Z., Li, X., Zhang, Z., et al. (2023) · Microbiological Research · doi:10.1016/j.micres.2023.127470 · Cited by 16
Tsunedomi, R., Shindo, Y., Nakajima, M., Yoshimura, K., & Nagano, H. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2281482 · Cited by 15
“The mechanism is explained by enhanced inflammation and altered metabolism in the patients that affect the tumorigenic processes, such as cellular proliferation, invasion, metastasis, and angiogenesis [76–78].”
BackgroundLiang, P., Deng, H., Zhao, Y., Chen, Y., Zhang, J., He, J., & Liang, W. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-357 · Cited by 14
Wang, K., Zhang, J., Zhang, Y., Xue, J., Wang, H., Tan, X., Jiao, X., & Jiang, H. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1288666 · Cited by 17
“The gut microbiota signi fi cantly in fl uences the development, progression, metastasis, and therapeutic response of CRC (Garrett, 2015).”
BackgroundZhang, L., & Yu, L. (2024) · Medicine · doi:10.1097/md.0000000000038078 · Cited by 16
“[5] Garrett et al [6] reported 3 ways in which the microbiota may lead to tumor progression and development: (1) changing the balance of cell proliferation and apoptosis, (2) reprogramming the immune system and responses, and (3) affecting the metabolism of host-secreted factors, foods, and drugs.”
BackgroundJi, G., Zhao, J., Si, X., & Song, W. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115345 · Cited by 18
Metadata
- Authors
- Garrett, W. S.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Garrett, Wendy S.
- ORCID
- Garrett, Wendy S.
- Venue
- Science
- Published
- 2015-04-03
- Volume
- 348
- Issue
- 6230
- Pages
- 80-86
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5535753
- OpenAlex
- W2073924079
- Cited by
- 1,404
- References
- 119
- Citations by year
- 2026: 145 · 2025: 169 · 2024: 169 · 2023: 151 · 2022: 162 · 2021: 141 · 2020: 127 · 2019: 106 · 2018: 77 · 2017: 68 · 2016: 58 · 2015: 29
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (R01CA154426)
- Burroughs Wellcome Career in Medical Sciences Award
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- gut microbiota, cancer susceptibility, carcinogenesis, host-microbe interactions, cancer therapy response, cancer diagnosis
- MeSH terms
- Humans, Immunotherapy, Neoplasms, Carcinogenesis, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.